Joseph J. Palermo

Joseph J. Palermo

Auto-generated profile, based on publicly available information

Joseph J. Palermo

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DLDaniel H. Leung
Daniel H. Leung
WYWen Ye
Wen Ye
SSSarah J. Schwarzenberg
Sarah J. Schwarzenberg
AFAlvin Jay Freeman
Alvin Jay Freeman
JPJoseph J. Palermo
Joseph J. Palermo
JMJean P. Molleston
Jean P. Molleston

7 April 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
PDF file
MSMarilyn J Siegel
Marilyn J Siegel
DLDaniel H. Leung
Daniel H. Leung
JMJean P Molleston
Jean P Molleston
WYWen Ye
Wen Ye
SPShruti M Paranjape
Shruti M Paranjape
MNMichael R Narkewicz
Michael R Narkewicz

15 April 2026 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
WYWen Ye
Wen Ye
SHSuiyuan Huang
Suiyuan Huang
MBMolly Bozic
Molly Bozic
BKBoaz Karmazyn
Boaz Karmazyn
RHRoger Harned
Roger Harned
AFAlvin Jay Freeman
Alvin Jay Freeman

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
MKMansa Krishnamurthy
Mansa Krishnamurthy
TBTaylor R. Broda
Taylor R. Broda
DKDaniel O. Kechele
Daniel O. Kechele
XZxinghao zhang
xinghao zhang
JPJoseph J. Palermo
Joseph J. Palermo
JWJames Wells
James Wells
Pancreas and gastrointestinal (GI) tract development is guided by several transcription factors, including pancreatic and duodenal homeobox gene-1 (PDX1). While it is well known that PDX1is essential for pancreatic development and beta cell function, its role in GI development and function is not fully understood. We identified a patient with a homozygous point mutation in PDX1 causing total loss of PDX1 protein resulting in pancreatic agenesis. We differentiated induced pluripotent stem cells from the patient into human antral gastric (HAGO) and intestinal (HIO) organoids as a novel diagnostic approach to identify new GI pathologies. Immunofluorescence staining revealed that portions of the PDX1-null HAGOs lost the gastric marker claudin18 and increased intestinal villin1 expression, signifying that regions of the antrum are converting to an intestinal phenotype. Similarly, PDX1-null HIOs lost the intestinal marker cadherin17 and increased claudin18, indicating that regions of the intestine are undergoing gastric metaplasia. Examination of functional markers revealed an increase in acid producing parietal cells, complete lack of gastrin producing endocrine cells in HAGOs, and an increase in gastric surface mucin in HIOs. These in vitro results were further validated using endoscopy biopsies from two patients with PDX1 mutations, which showed a similar disruption in gastric and intestinal identity. CRISPR/Cas9-mediated correction of the PDX1 mutation reversed the observed PDX1-null metaplasic phenotypes in HAGOs and HIOs and also allowed for the successful generation of pancreatic tissue indicating unambiguously that the PDX1 mutation is responsible for these pathologies. Based on these findings, these PDX1-null patients will have additional screening to monitor the progression of metaplasia into gastric and intestinal cancer. This study further demonstrates the utility of organoids in improving patient diagnoses and treatment. Disclosure M. Krishnamurthy: None. T.R. Broda: None. D.O. Kechele: None. X. Zhang: None. J.J. Palermo: None. M.H. Collins: None. I.H. Thomas: None. A. Heider: None. A. Dauber: None. J. Wells: None. Funding American Diabetes Association (1-19-PDF-036 to M.K.)